A review of the SWEDEHEART NSTEMI anticoagulant trial - Fondaparinux versus low-molecular-weight heparin in patients with non-ST-segment elevation myocardial infarction.
The study involved 40,616 consecutive patients treated for an NSTEMI event at 72 Swedish hospitals between 2006 and 2010. Commentary is provided by Dr Christopher Hammett, an Interventional Cardiologist at the Royal Brisbane and Women’s Hospital, Brisbane Queensland.
Please login below to download this issue (PDF)